3 results
Primairy objectivesTo study the pharmacokinetics (plasma and cerebrospinal fluid) of meropenem in infants <= 90 days of postnatal age with probable or confirmed bacterial meningitis (BM); To describe the safety profile of meropenem in the…
To assess if short antibiotic treatment (3x24 hours) with an anti-pseudomonal carbapenem (imipenem-cilastatin or meropenem) is safe (NON-INFERIOR) with regard to treatment failure in comparison with extended treatment (at least 9x24hours) of high-…
What is the level of agreement between the gold standard, which includes invasive DO2 and VO2 measurements (with pulmonary artery catheter and central venous line), when compared with DO2 and VO2 measurements derived by a minimal invasive approach (…